Intervention Protocol

Adefovir dipivoxil versus other antiviral drugs for chronic hepatitis B

  1. Basile Njei1,*,
  2. Sushil Kumar2,
  3. Eugene J Kongnyuy3

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 7 DEC 2011

Assessed as up-to-date: 2 NOV 2011

DOI: 10.1002/14651858.CD009522


How to Cite

Njei B, Kumar S, Kongnyuy EJ. Adefovir dipivoxil versus other antiviral drugs for chronic hepatitis B (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD009522. DOI: 10.1002/14651858.CD009522.

Author Information

  1. 1

    University of Connecticut School of Medicine, Department of Medicine, Farmington, Connecticut, USA

  2. 2

    All India Institute of Medical Sciences, New Delhi, Delhi, India

  3. 3

    Reproductive Health Solutions, Salisbury, UK

*Basile Njei, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, Connecticut, 06030, USA. basilenjei@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 7 DEC 2011

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the benefits and harms of adefovir dipivoxil alone or in combination with other drugs, as compared with antiviral drugs, in the treatment of patients with chronic hepatitis B virus infection. We will exclude comparisons that are already studied in other Cochrane Reviews on antiviral drugs for HBV infection (Katz 2010).